Skip to main content

Posts

Showing posts with the label tata1

Cilostazole used, Side, Doses, mechanism of action & more

Cilostazole Brand name:- Pletoz, Cilodoc, Stiloz 50, 100mg tabs.  Cilostazol widens the blood vessels and decreases the stickiness of the platelets, thereby increasing the blood flow to the lower limbs. Pharmacodynamic:-  Cilostazol reduces the symptoms of intermittent claudication, as indicated by an increased walking distance. Intermittent claudication is pain in the legs that occurs with walking and disappears with rest. The pain occurs due to reduced blood flow to the legs. Mechanism of action:-  Cilostazol and several of its metabolites are cyclic AMP (cAMP) phosphodiesterase III inhibitors (PDE III inhibitors), inhibiting phosphodiesterase activity and suppressing cAMP degradation with a resultant increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation. Used:-  Cilostazol is used in the treatment of intermittent claudication. It helps in reducing the symptoms of intermittent claudication like pain, crampin...

Celecoxib Uses, Side Effects, and More

 Celecoxib  Brand name:- Celact, Revibra , Colcibra 100, 200mg caps Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) called COX-2 inhibitors. It works by blocking the release of certain chemical messengers that are responsible for pain and inflammation (redness and swelling). Pharmacodynamic:-  Celecoxib inhibits cyclooxygenase 2 (COX-2) enzyme, reducing pain and inflammation. It is important to note that though the risk of bleeding with celecoxib is lower than with certain other NSAIDS, it exists nonetheless and caution must be observed when it is administered to those with a high risk of gastrointestinal bleeding. A note on the risk of cardiovascular events Significant concerns regarding the safety of COX-2 selective NSAIDs emerged in the early 2000s. Rofecoxib, another member of the COX-2 inhibitor drug class, also known as Vioxx, was withdrawn from the market due to prothrombotic cardiovascular risks.Following an FDA Advisory Committee meeting in 2005, in w...